{
    "eid": "2-s2.0-85124312940",
    "title": "Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Piyada Sitthideatphaiboon",
        "Chinachote Teerapakpinyo",
        "Krittiya Korphaisarn",
        "Nophol Leelayuwatanakul",
        "Nopporn Pornpatrananrak",
        "Naravat Poungvarin",
        "Poonchavist Chantranuwat",
        "Shanop Shuangshoti",
        "Chatchawit Aporntewan",
        "Wariya Chintanapakdee",
        "Virote Sriuranpong",
        "Chanida Vinayanuwattikun"
    ],
    "citedby-count": 11,
    "ref-count": 54,
    "ref-list": [
        "A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)",
        "The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis",
        "High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand",
        "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma",
        "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial",
        "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR",
        "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study",
        "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial",
        "First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label ENSURE study",
        "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations",
        "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial",
        "Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib",
        "Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib",
        "Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations",
        "Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review",
        "Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study",
        "Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer",
        "Mutation profiling of lung cancers with long-term response to gefitinib therapy",
        "Genomic landscape of lung adenocarcinoma in East Asians",
        "Reliable analysis of clinical tumor-only whole-exome sequencing data",
        "Oncogenic signaling pathways in the cancer genome atlas",
        "Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer",
        "An accurate and comprehensive clinical sequencing assay for cancer targeted and immunotherapies",
        "Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer",
        "A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases",
        "The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: A meta-analysis of prospective randomized trials",
        "Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma",
        "Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)",
        "PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR",
        "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling",
        "MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients",
        "Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis",
        "Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis",
        "Cancer genome landscapes",
        "Cancer genes and the pathways they control",
        "Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors",
        "Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers",
        "MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer",
        "LBA50\u2014Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study",
        "Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment",
        "Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors",
        "Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer",
        "Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC",
        "Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer",
        "A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells",
        "The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival",
        "CDK4 is an essential insulin effector in adipocytes",
        "CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation",
        "Efficacy of the CDK4/6 dual inhibitor abemaciclib in EGFR-mutated NSCLC cell lines with different resistance mechanisms to osimertinib",
        "Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion",
        "GOPC-ROS1 rearrangement as an acquired resistance mechanism to osimertinib and responding to crizotinib combined treatments in lung adenocarcinoma",
        "Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors",
        "Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers",
        "PureCN: Copy number calling and SNV classification using targeted short read sequencing"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn Academic Advancement",
        "Ratchadapiseksompotch Fund",
        "Chulalongkorn University",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}